9.99
-0.31
(-3.01%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 9.94 - 10.54 |
| 52 week | 7.21 - 12.77 |
| Open | 10.38 |
| Vol / Avg. | 1.54M/1.51M |
| Mkt cap | 815.19M |
| P/E | - |
| Div/yield | - |
| EPS | -3.04 |
| Shares | 81.60M |
| Beta | 2.26 |
| Inst. own | 103% |
Events
Jul 24, 2013
Q2 2013 InterMune Earnings Release
May 30, 2013
InterMune Annual Shareholder Meeting
- 1:00PM EDT -
May 15, 2013
InterMune at Bank of America Merrill Lynch Health Care Conference
Apr 26, 2013
Q1 2013 InterMune Earnings Release
Apr 24, 2013
Q1 2013 InterMune Earnings Conference Call -
Feb 25, 2013
InterMune at Citi Global Healthcare Conference
Feb 25, 2013
InterMune at Canaccord Genuity Orphan Drug Day
Feb 21, 2013
Q4 2012 InterMune Earnings Conference Call -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -475.83% | -705.62% |
| Operating margin | -528.00% | -743.52% |
| EBITD margin | - | -735.12% |
| Return on average assets | - | -44.18% |
| Return on average equity | - | -139.66% |
| Employees | 269 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
InterMune, Inc. (InterMune), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, the Company began the commercial launch of Esbriet in Canada. June 19, 2012, the Company completed the divestiture of its worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by the Company under the tradename Actimmune. On June 19, 2012, the Company sold the rights of Actimmune (interferon gamma-1b) to Vidara Therapeutics International Limited.
Officers and directors
| Daniel G. Welch | Chairman of the Board, President, Chief Executive Officer | |
| John C. Hodgman | Chief Financial Officer, Senior Vice President - Finance | |
| Jonathan A. Leff | Executive Vice President - Research and Development | |
| Sean P. Nolan | Executive Vice President, Chief Business Officer | |
| Robin J. Steele Esq. | Senior Vice President, General Counsel, Corporate Secretary | |
| Giacomo Di Nepi | Senior Vice President, Managing Director, Europe | |
| Paul D. Arata | Senior Vice President - Human Resources and Administration | |
| Lars G. Ekman M.D., Ph.D. | Lead Independent Director | |
| Jean-Jacques Bienaime | Independent Director | |
| Louis Drapeau | Independent Director |